Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Stenocare AS's Debt-to-EBITDA or its related term are showing as below:
FRA:S7C'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.2 Med: -0.77 Max: 7.43
Current: 7.43
During the past 8 years, the highest Debt-to-EBITDA Ratio of Stenocare AS was 7.43. The lowest was -1.20. And the median was -0.77.
FRA:S7C's Debt-to-EBITDA is ranked worse than 88.55% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs FRA:S7C: 7.43
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Stenocare AS Debt-to-EBITDA Related Terms
Stenocare AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Stenocare AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S7C vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Stenocare AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Stenocare AS (FRA:S7C) has a Debt-to-EBITDA of 6.38 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Stenocare AS. According to the industry distribution chart, Stenocare AS ranks #603 out of 681 companies in the Drug Manufacturers industry, placing it in the top 88.5%.
Is Stenocare AS's Debt-to-EBITDA too high?
Stenocare AS's current Debt-to-EBITDA is 6.38. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Stenocare AS's value of 6.38 is 291.4% above this industry median. Based on the distribution chart, Stenocare AS ranks #603 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #603 out of 681 companies for Debt-to-EBITDA. This places Stenocare AS in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Stenocare AS's value of 6.38 is 291.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stenocare AS's current Debt-to-EBITDA of 6.38 is 291.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Stenocare AS. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current Debt-to-EBITDA is 6.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Stenocare AS (FRA:S7C) has a current Debt-to-EBITDA of 6.38. The stock's GF Value™ is €0.30, compared to a current price of €0.12 — trading 59.8% below its estimated fair value. The current Debt-to-EBITDA is 6.38 and 291.4% above the Drug Manufacturers industry median of 1.63. Stenocare AS's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Stenocare AS (FRA:S7C), the current Debt-to-EBITDA is 6.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (FRA:S7C) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of €0.12 is trading 59.8% below its estimated GF Value™ of €0.30.
Key valuation signals for FRA:S7C:
Debt-to-EBITDA: 6.38
GF Value™: €0.30 vs. price of €0.12 (59.8% below fair value)
Industry Position: 291.4% above the Drug Manufacturers median (#603 of 681)
No single metric tells the full story. See the FRA:S7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
44GF Score
Get the complete analysis for FRA:S7C
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S7C has been successfully added to your 
